Dalosirvat

Last updated

Dalosirvat
Dalosirvat.svg
Clinical data
Other namesSM-04554; SM04554
Routes of
administration 		Topical solution [1] [2]
Drug class Wnt signaling pathway stimulant
ATC code
  • None
Identifiers
  • 1-(2,3-dihydro-1,4-benzodioxin-6-yl)-4-phenylbutane-1,4-dione
CAS Number
PubChem CID
DrugBank
UNII
ChEMBL
Chemical and physical data
Formula C18H16O4
Molar mass 296.322 g·mol−1
3D model (JSmol)
  • C1COC2=C(O1)C=CC(=C2)C(=O)CCC(=O)C3=CC=CC=C3
  • InChI=1S/C18H16O4/c19-15(13-4-2-1-3-5-13)7-8-16(20)14-6-9-17-18(12-14)22-11-10-21-17/h1-6,9,12H,7-8,10-11H2
  • Key:AOCDRSSVFUCURK-UHFFFAOYSA-N

Dalosirvat (INN Tooltip International Nonproprietary Name, USAN Tooltip United States Adopted Name; developmental code name SM-04554) is a drug acting as a Wnt signaling pathway stimulant which is under development for the treatment of alopecia (hair loss). [1] [3] [2] [4] It is used topically as a solution. [1] [2] The drug is being developed by Biosplice Therapeutics (formerly known as Samumed). [1] [3] As of April 2021, it is in phase 2/3 clinical trials for this in Turkey. [1] [3] There have been no further updates on the development of dalosirvat as of October 2025. [1] Two phase 2 trials have been completed and preliminary results released. [2] In one of the trials, only a 0.15% concentration and not a higher 0.25% concentration showed effectiveness. [2] A 625-patient phase 3 trial was reportedly started in 2018. [2] It was reported in a 2023 literature review that dalosirvat had completed a phase 3 trial in early 2023 and that Biosplice Therapeutics had cancelled its development based on the trial's results. [5]

Contents

See also

References

  1. 1 2 3 4 5 6 "Biosplice Therapeutics". AdisInsight. 19 April 2021. Retrieved 23 October 2025.
  2. 1 2 3 4 5 6 Ocampo-Garza J, Griggs J, Tosti A (March 2019). "New drugs under investigation for the treatment of alopecias". Expert Opinion on Investigational Drugs. 28 (3): 275–284. doi:10.1080/13543784.2019.1568989. PMID   30642204.
  3. 1 2 3 Keown A (18 October 2025). "Delving into the Latest Updates on SM-04554 with Synapse". Synapse. Retrieved 23 October 2025.
  4. ↑ Goswami VG, Patel BD (November 2021). "Recent updates on Wnt signaling modulators: a patent review (2014-2020)". Expert Opinion on Therapeutic Patents. 31 (11): 1009–1043. doi:10.1080/13543776.2021.1940138. PMID   34128760.
  5. ↑ Castro AR, Portinha C, Logarinho E (June 2023). "The booming business of hair loss". Trends in Biotechnology. 41 (6): 731–735. doi:10.1016/j.tibtech.2022.12.020. PMID   36669948. Embryonic conserved signaling pathways that have been consistently associated with hair cycle regulation and trichogenicity are Wingless (Wnt), Sonic hedgehog (Shh), Hairy and enhancer of split 1 (Hes1), fibroblast growth factor 7 (FG7), and keratinocyte growth factor (KGF). The Wnt/β-catenin signaling pathway has a key role in hair morphogenesis and cycling during both the embryonic stage and adult life. Therefore, pharmacological activation of the Wnt/β-catenin signaling has been explored for a long time to promote hair regeneration. Samumed (now Biosplice) was the first company to develop a topical solution for Wnt signaling activation in the balding scalp. Biosplice managed to value $12 billion in 2018, but earlier this year, upon conclusion of a phase 3 clinical trial, Biosplice canceled dalosirvat from clinical development.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.